nasal spray:dead sea spray+sea spray+af Iżrael - Ebrajk - Ministry of Health

nasal spray:dead sea spray+sea spray+af

medicure technologies ltd - כלל האוכלוסיה - תמיסת מלח בספריי לשטיפה עדינה של מערות האף

diag. kits for krohn's disease Iżrael - Ebrajk - Ministry of Health

diag. kits for krohn's disease

glycominds ltd. - אחות - ערכות דיאג. לסיוע באבחון מחלת קרוהן

פלאג'יל 250 מג טבליות Iżrael - Ebrajk - Ministry of Health

פלאג'יל 250 מג טבליות

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

סנדאימון   ניאורל   50 מג כמוסות Iżrael - Ebrajk - Ministry of Health

סנדאימון ניאורל 50 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

סנדאימון   ניאורל   100 מג כמוסות Iżrael - Ebrajk - Ministry of Health

סנדאימון ניאורל 100 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

DURASEAL Iżrael - Ebrajk - Ministry of Health

duraseal

קובידיאן (ישראל) בע"מ - מומחה - dural sealant

PLEURASEAL Iżrael - Ebrajk - Ministry of Health

pleuraseal

קובידיאן (ישראל) בע"מ - מומחה - lung sealant

סטאלבו   10025200 מג Iżrael - Ebrajk - Ministry of Health

סטאלבו 10025200 מג

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

סטאלבו   5012.5200 מג Iżrael - Ebrajk - Ministry of Health

סטאלבו 5012.5200 מג

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

רנוולה אבקה 2.4 גרם Iżrael - Ebrajk - Ministry of Health

רנוולה אבקה 2.4 גרם

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.